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Background:  Young  infants  have  reduced  susceptibility  to  febrile  malaria  compared  with  older  children,
but the  mechanism  for this  remains  unclear.  There  are conﬂicting  data  on  the  role  of  passively  acquired
antibodies.  Here,  we  examine  antibody  titres  to  merozoite  surface  antigens  in the  protection  of  children
in  their  ﬁrst  two years  of  life  in two  settings  with  differing  malaria  transmission  intensity  and  compare
these  titres  to  previously  established  protective  thresholds.
Methods:  Two  cohorts  of children  aged four  to six weeks  were  recruited  in  Banfora,  Burkina  and  Keur  Soce,
Senegal and  followed  up  for two years.  Malaria  infections  were  detected  by light  microscopic  examina-
tion  of blood  smears  collected  at active  and  passive  case  detection  visits.  The  titres  of  antibodies  to  the
Plasmodium  falciparum  recombinant  merozoite  proteins  (AMA1-3D7,  MSP1-19,  MSP2-Dd2,  and  MSP3-
3D7)  were  measured  by  enzyme-linked  immunosorbent  assay  at  1–6,  9, 12,  15  and  18 months  of  age  and
compared  with  the  protective  thresholds  established  in  Kenyan  children.
Results:  Antibody  titres  were below  the protective  thresholds  throughout  the  study  period  and  we  did  not
ﬁnd any  association  with  protection  against  febrile  malaria.  Antibodies  to  AMA1  and  MSP1-19  appeared
to  be markers  of  exposure  in  the  univariate  analysis  (and  so  associated  with  increasing  risk)  and  adjusting
for exposure  reduced  the strength  and  signiﬁcance  of  this  association.
Conclusion:  The  antibody  levels  we  measured  are  unlikely  to be responsible  for the  apparent  protection
against  febrile  malaria  seen  in young  infants.  Further  work  to identify  protective  antibody  responses
might  include  functional  assays  and  a wider  range  of  antigens.
ublis© 2015  The  Authors.  P. Introduction
Evidence of the protective effect of antibodies against Plasmo-
ium falciparum febrile malaria was consistently demonstrated in
herapeutic passive transfer experiments [1–4]. Infants passively
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acquire maternal antibodies, mainly IgG, by placental transfer
[5]. Concurrently, transplacental passage of malaria antigens may
prime foetal T and B cells and trigger IgM and IgG production
[6], although this may  be associated with immunosuppression [7].
Infants may  be infected [8] but are less likely to develop clinical
manifestations of malaria [9] compared with older children. Apart
from maternally acquired antibodies, other biological [10], nutri-
tional [11] and physical factors [12], may  play an important role
in this apparent early and short-lived protection against febrile
malaria. Most studies suggest that the reduced susceptibility to
malaria lasts until around four months of age [8,13–16].
A number of sero-epidemiological ﬁeld studies have investi-
gated the determinants of naturally acquired immunity in children
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
accine
a
s
b
t
s
r
[
t
G
b
a
t
e
c
c
p
r
F
t
s
t
a
2
2
o
d
F
C
u
p
a
2
S
a
t
p
s
5
c
t
i
T
b
l
[
c
2
b
[
v
h
iD.T. Kangoye et al. / V
nd adults in various settings with differing malaria transmis-
ion levels. These studies have yielded inconsistent associations
etween anti-malaria antibodies and immunity to malaria [17]. In
he investigation of these conﬂicting results, it has been recently
hown that a threshold concentration of antibodies needs to be
eached to achieve protection against febrile malaria in children
18,19].
We  recently conducted a study in Burkina Faso examining
he impact of maternally-acquired antibodies against synthetic
LURP and MSP3 on the risk of malaria. We  found associations
etween increasing antibody levels and increasing risk of malaria,
nd no evidence of protective antibody responses. Limitations of
his previous study were the limited number of antigens that were
xamined, and the lack of standardised controls that meant we
ould not estimate relative antibody concentrations and therefore
ould not determine how close these antibody levels were to the
rotective thresholds.
The present malaria sero-epidemiological study expands the
ange of antibodies examined and includes standardised controls.
urthermore we describe below how antibody levels vary during
he ﬁrst 18 months of life in two settings with differing transmis-
ion intensity and we present the results of the analysis testing
he hypothesis of an association between total IgG to merozoite
ntigens and protection against P. falciparum febrile malaria.
. Methods
.1. Ethical statement
The ethical approval for the work in Burkina Faso was
btained from the Institutional Review Board of Centre National
e Recherche et de Formation sur le Paludisme (CNRFP) in Burkina
aso. In Senegal, the study was approved by the National Ethics
ommittee. The parents of each child were informed and an individ-
al written consent obtained prior to performing any study-speciﬁc
rocedure on the child. The studies in both settings were conducted
ccording to the principles of the Declaration of Helsinki.
.2. Study site and population
The study was conducted in Banfora, Burkina Faso and in Keur
oce, Senegal.
The Banfora site is described elsewhere [20,21]. Brieﬂy, the
nnual rainfall is above 900 mm with the rains lasting from May
o October. The transmission of malaria is stable and seasonal. The
arasite rates in children aged 2–10 years during the wet and dry
easons in the year preceding the study start were 67.22% and
3.55% respectively. From November 2010 to February 2011,140
hildren aged four to six weeks were recruited into a prospec-
ive longitudinal cohort study. In Keur Soce, the annual rainfall
s less than Banfora, at 300 mm with rains from July to October.
ransmission of malaria has previously been stable and seasonal,
ut has recently reduced [22]. The parasite rate in children aged
ess than ten years and living in Keur Soce was 0.3% in 2010
23]. A total of 150 infants were recruited into the Keur Soce
ohort.
.3. Surveillance of malaria morbidity
In both sites, febrile malaria cases were detected using a com-
ination of active and passive monitoring as detailed elsewhere
21]. The active case detection consisted in scheduled weekly home
isits conducted by study nurses to check the children’s
ealth status and collect blood ﬁlms for microscopy when
ndicated. 34 (2016) 160–166 161
2.4. Parasitological examination and haemoglobin typing
The identiﬁcation and quantiﬁcation of malaria parasites were
done as described elsewhere [20]. In brief, each blood smear was
examined by two independent microscopists and their respec-
tive results were compared for consistency. When their results
were concordant, the average was recorded as the ﬁnal result;
otherwise the same blood smear was  examined by a third micros-
copist and the ﬁnal result was  the average of the two most
concordant parasite densities. Fractions of foetal haemoglobin and
haemoglobin variants were measured using High Pressure Liquid
Chromatography.
2.5. Selection of samples for serological tests
For a subset of 40 children in each site (sampled randomly with-
out replacement from among all children with complete samples
sets available using Stata 13.1), samples at baseline, 2, 3, 4, 5, 6, 9, 12,
15 and 18 months were analysed to compare antibody dynamics.
The samples of the remaining children in the Banfora cohort were
analysed only at baseline, 3, 6, 9, 12 and 18 months and included
in the analysis of the association between antibody levels and risk
of clinical malaria in that cohort.
2.6. Plasmodium falciparum merozoite antigens tested in the
assays
The following four recombinant merozoite antigens were tested
in this study: the His-tagged AMA1 of the 3D7 allelic form [24], the
GST-tagged MSP1-19 of the Wellcome parasite line [25], the GST-
tagged MSP2 of the Dd2 parasite line [26] and the MBP-tagged MSP3
of the 3D7 allelic form [27].
2.7. Antibody titres measurement by direct ELISA
Serum total IgG titres were measured as described elsewhere
[18] with the serum samples diluted at 1:500. The assays test-
ing AMA1-3D7, MSP2-Dd2 and MSP3-3D7 were done in duplicates
for the ﬁrst 372 samples (representing 26% of the total number of
samples to analyse) to estimate the variability (coefﬁcient of vari-
ation, CV) between the duplicates. We  met  a pre-set criterion that
<5% of sample pairs had a CV > 20 (i.e. 0%, 0.81% and 1.88% respec-
tively for responses to AMA1-3D7, MSP2-Dd2 and MSP3-3D7) and
so proceeded with assays in singles rather than duplicates. After
adjusting optical densities (ODs) for day to day variation, for anti-
gens that are GST or MBP-tagged, the actual OD of each sample was
obtained by subtracting the OD of the tag. A four-parameter logistic
regression was  used to model the relationship between serial dilu-
tions of a puriﬁed IgG standard (Malaria Immune Globulin (MIG)
reagent from the Central Laboratory Blood Transfusion Service
SRC, Switzerland) of known concentration and the correspond-
ing ODs, and therefore to allow conversion of the study samples
ODs into antibody concentrations. Antibody concentrations were
then transformed into arbitrary units (AU) as previously described
[18].
3. Statistical methods
3.1. Analysis of the dynamics of antibody titres
We used Pearson correlation test on log-transformed values to
measure how strong the relationship is between antibody levels
to a given antigen from one time point to the following one and
between antigen-speciﬁc antibody titres. To estimate the overall
decline of antibodies, we used a Random-Effects regression model
of antibody titres on age to account for between and within-infant
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ariability of antibody titres. We  calculated the cut-off value for
eropositivity as the mean OD of negative controls plus 3 standard
eviations. Fisher’s Exact test was used to compare seroprevalence
f antibodies to the P.f. merozoite antigens between both the sites
t baseline. Fractional polynomial regression models were con-
tructed to ﬁt the non-linear relationship between anti-malaria
ntibody titre and age. The protective thresholds (for antibodies
o AMA1-3D7, MSP1-19, MSP2-Dd2 and MSP3-3D7) displayed in
he graphs have been taken from the results of studies conducted
y Murungi et al. in the Kenyan Coast [18]. Brieﬂy, they used a
odiﬁed Poisson regression to model the association between the
isk of clinical malaria and antibody concentration categorised into
igh vs low responders using a series of arbitrary cut-offs within
he range of the levels measured in their study children. The pro-
ective threshold concentration was then selected based on the
og pseudolikelihood. These thresholds have then been validated
n a second independent cohort of lower transmission intensity
n Kenya [18]. The same methods were used to derive protec-
ive thresholds in a children cohort study in Coastal Tanzania
19].
.2. Analysis of correlates of protection
The outcome measure, febrile malaria, was deﬁned as the associ-
tion of fever (axillary temperature ≥37.5 ◦C and/or reported fever
n the past 24 h) plus asexual parasitemia ≥10,000/L [21]. An
ndividual malaria exposure index was calculated for each child.
rieﬂy, we have adapted the method of Olotu et al. based on local
alaria prevalence and computed instead, individual malaria expo-
ure indexes based on time-to-ﬁrst malaria infection as described
lsewhere [21]. We  have investigated the relationship between
he putative correlates of protection (seropositivity and antibody
itres) and febrile malaria using two approaches. First, we  used Cox
roportional hazards regression to model the relationship between
ntibodies and time to ﬁrst febrile malaria episode, and tested the
roportional hazards assumption using the Kaplan Meier method
nd the Schoenfeld residuals. The second approach consisted of
odelling the relationship between antibodies and the number
f febrile malaria episodes experienced using a negative binomial
egression with the Huber-White Sandwich estimator to account
or clustering by individual. In the latter approach, the analysis
eriod was restricted to the three months following each time
oint for malaria serology to account for the short half-life of anti-
alaria antibodies [28]. The antibody titres of the study samples
ere included in the models as time-changing covariates with the
easured value at the beginning of each interval related to the
ebrile episodes recorded within this interval. The overall signiﬁ-
ance of categorical variables was estimated using the Wald test.
ll the antibody titres used in the data analysis are arbitrary units
n log scale. The data was analysed using GraphPad Prism version
.00 for Windows, GraphPad Software and Stata 13.1 for Windows,
tataCorp LP.
. Results
.1. Malaria morbidity
The characteristics of the Banfora infant cohort, follow up and
alaria morbidity are described in detail elsewhere [21]. Brieﬂy,
96 febrile malaria episodes were recorded over 249 child-years
ith the number of cases peaking in October each year, giving
n incidence rate of 1.2 episodes/child/year (95%CI, 1.06–1.33). In
he ﬁrst six months of life, ﬁve infections (two asymptomatic and
hree febrile) were detected, of which three occurred in the rains,
n children aged above ﬁve months. In Keur Soce only 4 episodes of 34 (2016) 160–166
asymptomatic malaria were identiﬁed in the cohort of 150 infants,
and no symptomatic episodes were identiﬁed. This is consistent
with long-term trends of malaria described elsewhere in Northern
Senegal [22].
4.2. Variability of antibody titres with time and transmission
intensity
At baseline, the seroprevalence of the merozoite antigens was
signiﬁcantly higher in the Banfora cohort compared with Keur Soce
cohort except for antibodies to MSP1-19 (Table S2). After a steady
decline in the ﬁrst six months of life regardless of the transmis-
sion intensity, the seroprevalence to all the antigens tested held
below 20% for the remaining monitoring period in Keur Soce, the
low transmission area. In Banfora where the transmission is higher,
the seroprevalence peaked after six months for MSP1-19 and MSP3-
3D7 (Fig. S1). Only anti-MSP2 antibodies increased appreciably
from month 9 (Fig. 2). No conﬁdence interval was reported for the
protective thresholds; however, the antibody levels in our cohorts
were mostly well below the protective thresholds throughout the
follow up (Fig. 1). The average antibody decay rates were similar in
both the sites only for antibodies to MSP1-19, higher in Banfora for
MSP2-Dd2 and MSP3-3D7 and moderately higher in Keur Soce for
AMA1-3D7 (Table S3).
Antibody titres to AMA1-3D7, MSP1-19, MSP2-Dd2, MSP3-3D7
were strongly correlated from time point to time point during the
ﬁrst six months of life in both settings regardless of the transmis-
sion intensity (r, 0.86–0.98 in Keur Soce, 0.86–0.91 in Banfora for
AMA-1) (Fig. S3). After the ﬁrst 6 months of life, antibody titres
were weakly to moderately correlated to each other in Keur Soce
(r, 0.21–0.47) but not correlated in Banfora (−0.21 to 0.03).
4.3. Relationship between antibodies and incidence of febrile
malaria
4.3.1. Univariate analysis
This analysis applies to Banfora only. In the time-to-event
univariate analysis none of the antigen-speciﬁc antibodies, in
terms of levels or seropositivity, was  associated with protection.
Antibodies to AMA1-3D7 (HR: 1.34, 95%CI: 1.11–1.62, p = 0.002)
and MSP1-19 (HR: 1.44, 95%CI: 1.19–1.74, p < 0.001) were sig-
niﬁcantly associated with a higher risk of febrile malaria but
season was  the strongest signiﬁcant risk factor for febrile malaria
(HR: 8.28, 95%CI: 2.18–31.44, p = 0.002). The results of the event
count analysis were similar except for anti-AMA1-3D7 antibodies
that appeared as signiﬁcantly associated with protection against
febrile malaria episodes (HR: 0.89, 95%CI: 0.80–0.98, p = 0.015).
Children with haemoglobin CC type had lower risk of febrile
malaria compared with haemoglobin AA children. Age was a sig-
niﬁcantly associated with risk of febrile malaria (Table S4). In
both models, the highest level of education was signiﬁcantly
associated with protection and children born in the last quar-
ter of the year had signiﬁcantly lower risk of febrile malaria
compared with those born in January as previously described
[21].
4.4. Multivariable analysis
There was  only limited collinearity between the different
antibody titres (VIFs < 2; mean VIF = 1.44). In the multivariable
time-to-event analysis, foetal haemoglobin rate was  weakly
but signiﬁcantly associated with protection (HR: 0.97, 95%CI:
0.94–0.99, p = 0.004). Season remained the strongest risk factor
(HR: 9.39, 95%CI: 2.32–37.99, p = 0.002), and exposure index was
associated with a risk of malaria (HR: 1.10, 95%CI: 1.05–1.15,
p < 0.001). There was a tendency of anti-MSP1-19 antibodies to
D.T. Kangoye et al. / Vaccine 34 (2016) 160–166 163
Fig. 1. Comparative dynamics of individual antibody titres between Keur Soce and Banfora children. The dashed lines represent the protective thresholds established in
children living in the Kenyan Coast. Each line represents an individual trajectory of antibody concentration.
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aFig. 2. Trend lines of antibodies to P. falciparum mero
e associated with higher risk of febrile malaria (HR: 1.40, 95%CI:
.09–1.80, p = 0.008), but overall the correlation between antibod-
es and increased risk of malaria was reduced by adjusting for
xposure and season. There was no signiﬁcant deviation from the
roportional hazards assumption (Figs. 3 and S2). In the event
ount analysis, none of the antigen-speciﬁc antibodies was signif-
cantly associated with febrile malaria. Season was conﬁrmed as
he strongest risk factor (Table 1). An interaction of weak effect
ize between season and individual exposure index was observed
IRR = 1.06, 95%CI: 1.002–1.13, p = 0.042) in the event count
nalysis.antigens. Antibody concentrations are in log10 scale.
5. Discussion
The titres of antibodies to all the four antigens tested were below
the protective thresholds except for a few outlying results. After a
consistent decline up to six months of age, only antibodies to MSP2
showed a steady increase up to month 18 in the high transmission
setting (Banfora). Overall, we  did not ﬁnd any protective effect in
the investigation of the association between antibodies to P. fal-
ciparum merozoite antigens and febrile malaria. Antibody titres to
some merozoite antigens (AMA1-3D7 and MSP1-19) were rather
a maker of exposure to malaria, evidenced by the association with
164 D.T. Kangoye et al. / Vaccine 34 (2016) 160–166
Fig. 3. Estimation of children survival in relation to anti-malaria antibody tertiles. (A) antibodies to AMA1-3D7, (B) antibodies to MSP1-19, (C) antibodies to MSP2-Dd2, (D)
antibodies to MSP3-3D7.
Table 1
Multivariable models of risk of P. falciparum febrile malaria.
Cox proportional hazards model Negative binomial model
Predictor HR 95%CI p IRR 95%CI p
Age – – – 1.14 [1.09, 1.19] <0.001
Anti-AMA1 1.14 [0.92, 1.42] 0.216 1.05 [0.92, 1.20] 0.504
Anti-MSP1 1.40 [1.09, 1.80] 0.008 1.14 [0.99, 1.31] 0.052
Anti-MSP2 0.89 [0.63, 1.27] 0.528 0.87 [0.72, 1.02] 0.079
Anti-MSP3 1.20 [0.63, 2.27] 0.578 0.93 [0.66, 1.33] 0.704
Foetal Hb rate (baseline) 0.97 [0.94, 0.99] 0.004 0.98 [0.97, 0.99] 0.041
Haemoglobin type
AA 1 – – 1 – –
AS*  NA – 0.121 NA – <0.001
AC  1.75 [0.88, 3.51] 1.44 [0.95,2.19]
CC  0.28 [0.04, 2.19] 0.47 [0.15, 1.46]
ITN  use (pregnancy)
Yes 1 – – 1 – –
No  1.05 [0.47, 2.36] 0.912 1.32 [0.78, 2.25] 0.305
Month of birth
January – – – – – –
October 0.27 [0.07, 1.01] 0.269 0.49 [0.21, 1.16] 0.062
November 0.71 [0.34, 1.50] 0.91 [0.56, 1.50]
December 0.70 [0.36, 1.39] 1.14 [0.74, 1.73]
Season
r
f
f
d
s
ﬁ
o
aDry  season 1 
Rains  9.39 [2.32, 37.99] 
Malaria exposure index 1.10 [1.05, 1.15] 
isk and the fact that this association was diminished after adjusting
or the exposure index.
Average antibody decay rates were similar in both settings only
or antibodies to MSP1-19. Reduced exposure to infectious bites
uring the ﬁrst six months in the high and seasonal transmission
etting (Banfora) is a likely explanation of this similarity since only
ve malaria infections were detected during this period in Banfora,
f which three occurred in the ﬁrst rainy season in children aged
bove ﬁve months. The lack of acquisition of antibodies and the1 – –
0.002 3.17 [2.17, 4.62] <0.001
<0.001 1.08 [1.03, 1.12] 0.001
strong correlation of antibody levels between time points in Keur
Soce indicates lack of exposure throughout the monitoring period.
However in Banfora antibody levels were more variable from time
point to time point, indicating that exposure to malaria was stimu-
lating antibody production in some children, and furthermore that
increases in antibody titres were often transient (Fig. S3).
Few studies have examined the role of anti-malaria antibodies
in infants. We  found that anti-AMA1-3D7 antibodies appeared as
a marker of exposure (positively associated with the risk of febrile
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alaria) in our univariate analysis, which is consistent with the
onclusions of Riley et al. [29]. Furthermore, adjusting for expo-
ure using the exposure index attenuated the positive association
etween anti-AMA1 antibodies and increasing risk, consistent with
nti-AMA1 antibodies acting as a marker of exposure in our study.
ur results are also in keeping with the ﬁndings of previous stud-
es in older children [30,31]. Similarly, in our study, antibody titres
o MSP1-19, MSP2-Dd2 and MSP3-3D7 were not associated with
rotection as in other infant cohort studies [16,29,32].
The apparent variation in results between infants and older chil-
ren may  be explained by the presence of a protective threshold.
urungi et al. and Rono et al. have analysed two  independent
ohorts of children and established protective threshold concen-
rations for some merozoite antigens [18,19]. Even in a high
ransmission setting such as Burkina Faso, we found that antibody
itres in the ﬁrst six months of life for the four tested antigens were
ell below these protective threshold concentrations. Furthermore
here was no association with protection. We  conclude that these
aternally-derived antibodies are not the protective mechanism. If
he antibody levels are not protective in these infants then what is
he basis of their apparent early and short-lived protection period
gainst the clinical manifestation of malaria?
The possibilities are that other antibodies not measured in
ur work are related to protection [33], or that other antibody-
ediated mechanisms not correlated with ELISA measurements
re operating [34] or that other mechanisms operate such as nutri-
ional factors [11], foetal haemoglobin [10], less infectious bites due
o a reduced surface area [12,35]. Previous data on passive transfer
f antibodies from cord blood suggest that antibodies are involved
2].
. Conclusion
Even at high intensity of malaria transmission, antibody levels to
he tested P. falciparum merozoite antigens (AMA1-3D7, MSP1-19,
SP2-Dd2 and MSP3-3D7) remained low compared with the previ-
usly established protective threshold concentrations. In addition,
he antibodies were not signiﬁcantly associated with a reduced risk
f malaria raising more questions on the basis of the early apparent
rotection against febrile malaria.
However, these results should be interpreted with caution
ecause of the limitations of this study. The protective thresholds
sed in the present study have been established in cohorts includ-
ng children more than 2 years old in addition to infants. In our
ohort, the lack of any protective effect did not allow us to deter-
ine speciﬁc thresholds for this age group. Furthermore, the timing
f the study, in which the ﬁrst few months of life overlapped with
he low malaria transmission season, was not ideal to assess the
ole of maternal antibodies at the higher titres seen in the ﬁrst few
onths of life. However, if antibody thresholds are related to real
iological phenomena than we would expect, the thresholds should
e similar across study sites and age group. Hence the main con-
ribution of our work is the demonstration that antibody levels in
nfants to selected merozoite antigens are well below previously
eﬁned protective thresholds, and therefore that these are unlikely
o be responsible for mediating protection in vivo. Further work to
dentify protective antibody responses might include assessment
f antibodies to other targets including red cell surface antigens,
nd functional assays in which the interaction of antibodies with
mmune cells is taken into account [34].cknowledgements
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